Shockwave Medical (SWAV) Tops Q4 EPS, Revenue; Guides Above Views

Shockwave Medical (NASDAQ: SWAV) reported Q4 EPS of $3.71, which may not compare to the analyst estimate of $1.00. Revenue for the quarter came in at $144 million versus the consensus estimate of $142.66 million.

GUIDANCE:

Shockwave Medical sees FY2023 revenue of $660-680 million, versus the consensus of $658.58 million.

For earnings history and earnings-related data on Shockwave Medical (SWAV) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Odysight.AI Inc. (ODYS) PT Lowered to $6 at Benchmark
• Benchmark Reiterates Buy Rating on Cineverse (CNVS) Ahead of Q4 Results